BL
CLRB icon

BFSG LLC’s Cellectar Biosciences CLRB Stock Holding History

BFSG LLC’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-33
Closed -$299 – 684
2024
Q4 		$299 Hold
33
– – ﹤0.01% 654
2024
Q3 		$2.14K Hold
33
– – ﹤0.01% 584
2024
Q2 		$2.5K Hold
33
– – ﹤0.01% 566
2024
Q1 		$3.98K Buy
+33
New +$3.58K ﹤0.01% 558

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFSG LLC's CLRB Position: Q1 2025 in Review

BFSG LLC sold out of Cellectar Biosciences (CLRB) in Q1 2025, closing a stake of 33 shares — an estimated $299 sold.

BFSG LLC first reported a position in CLRB in Q1 2024 and held it in 4 quarters. The position peaked at $3.98K in Q1 2024. 32 funds tracked by Wall St. Rank hold CLRB as of Q1 2025.

  • BFSG LLC reported no remaining Cellectar Biosciences position as of Q1 2025 after selling out during the quarter.
  • BFSG LLC sold 33 Cellectar Biosciences shares in Q1 2025, an estimated $299.
  • BFSG LLC first reported a position in Cellectar Biosciences in Q1 2024 and held it in 4 quarters.
  • BFSG LLC's Cellectar Biosciences position peaked at $3.98K in Q1 2024.
  • 32 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q1 2025.

Based on BFSG LLC's 13F filing for Q1 2025, filed 18 Apr 2025.